ValuEngine upgraded shares of Threshold Pharmaceuticals, Inc. (NASDAQ:MTEM) from a sell rating to a hold rating in a research report released on Thursday morning.

A number of other equities analysts have also weighed in on the stock. Ladenburg Thalmann Financial Services assumed coverage on shares of Threshold Pharmaceuticals in a research note on Thursday. They issued a buy rating and a $10.00 target price for the company. Stifel Nicolaus reaffirmed a hold rating and issued a $0.40 target price on shares of Threshold Pharmaceuticals in a research note on Thursday.

Threshold Pharmaceuticals (NASDAQ MTEM) traded up 14.18% during mid-day trading on Thursday, reaching $6.28. The company had a trading volume of 180,420 shares. The firm’s market cap is $40.87 million. Threshold Pharmaceuticals has a 12 month low of $3.85 and a 12 month high of $16.28.

Threshold Pharmaceuticals (NASDAQ:MTEM) last announced its earnings results on Monday, July 31st. The biotechnology company reported $0.22 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.77) by $0.99. The company had revenue of $3 million during the quarter. Equities analysts expect that Threshold Pharmaceuticals will post ($1.32) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/08/06/threshold-pharmaceuticals-inc-mtem-upgraded-to-hold-by-valuengine.html.

In other Threshold Pharmaceuticals news, Director Jeffrey W. Bird acquired 510,703 shares of Threshold Pharmaceuticals stock in a transaction dated Thursday, June 1st. The stock was bought at an average cost of $0.57 per share, for a total transaction of $291,100.71. Following the purchase, the director now directly owns 919 shares in the company, valued at approximately $523.83. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 12.97% of the company’s stock.

Threshold Pharmaceuticals Company Profile

Molecular Templates, Inc, formerly Threshold Pharmaceuticals, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib.

Receive News & Ratings for Threshold Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Threshold Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.